bo-653 and Coronary-Restenosis

bo-653 has been researched along with Coronary-Restenosis* in 1 studies

Reviews

1 review(s) available for bo-653 and Coronary-Restenosis

Article	Year
BO-653. Chugai. Current opinion in investigational drugs (London, England : 2000), 2003, Volume: 4, Issue:3 BO-653 is an antioxidant under development by Chugai for the potential treatment of atherosclerosis and the prevention of restenosis. By November 2001, BO-653 was in phase II trials for restenosis in post-percutaneous transluminal coronary angioplasty in the US, and by April 2002, the compound was in phase I trials for the same indication in Japan. Topics: Animals; Antioxidants; Arteriosclerosis; Benzofurans; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Coronary Restenosis; Humans	2003

Article

Year

Current opinion in investigational drugs (London, England : 2000), 2003, Volume: 4, Issue:3

BO-653 is an antioxidant under development by Chugai for the potential treatment of atherosclerosis and the prevention of restenosis. By November 2001, BO-653 was in phase II trials for restenosis in post-percutaneous transluminal coronary angioplasty in the US, and by April 2002, the compound was in phase I trials for the same indication in Japan.

Topics: Animals; Antioxidants; Arteriosclerosis; Benzofurans; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Coronary Restenosis; Humans

2003